Samsara BioCapital’s Recursion Pharmaceuticals RXRX Stock Holding History

Samsara BioCapital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-267,996	Closed	-$2.18M	–	57
2022 Q2	$2.18M	Sell	267,996 -271,240	-50%	-$1.81M	0.58%	31
2022 Q1	$3.86M	Hold	539,236	–	–	0.97%	28
2021 Q4	$9.24M	Sell	539,236 -213,703	-28%	-$4.02M	1.79%	14
2021 Q3	$17.3M	Sell	752,939 -22,644	-3%	-$642K	2.72%	12
2021 Q2	$28.3M	Buy	+775,583	New	+$23M	3.49%	9

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OMS

Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return

Samsara BioCapital's RXRX Position: Q3 2022 in Review

Samsara BioCapital sold out of Recursion Pharmaceuticals (RXRX) in Q3 2022, closing a stake of 267,996 shares — an estimated $2.18M sold.

Samsara BioCapital first reported a position in RXRX in Q2 2021 and held it in 5 quarters. The position peaked at $28.3M in Q2 2021. 146 funds tracked by Wall St. Rank hold RXRX as of Q3 2022.

Samsara BioCapital reported no remaining Recursion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Samsara BioCapital sold 267,996 Recursion Pharmaceuticals shares in Q3 2022, an estimated $2.18M.
Samsara BioCapital first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Samsara BioCapital's Recursion Pharmaceuticals position peaked at $28.3M in Q2 2021.
146 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2022.

Based on Samsara BioCapital's 13F filing for Q3 2022, filed 14 Nov 2022.